Isoflavone

Summary

Isoflavone (CHEMBL366460) is a phase-3 clinical-stage small molecule; indicated across 8 conditions including breast neoplasm and chronic kidney disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 8 conditions
• Clinical trials: 10
• Chemistry: 222.24 Da · C15H10O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL366460
Name	Isoflavone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	72304
ChEBI	CHEBI:18220
Molecular formula	C15H10O2
Molecular weight	222.24
InChIKey	GOMNOOKGLZYEJT-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C2=COC3=CC=CC=C3C2=O

IUPAC name: 3-phenylchromen-4-one

ChEBI definition: A simplest member of the class of isoflavones that is 4H-chromen-4-one in which the hydrogen at position 3 is replaced by a phenyl group.

Also known as: Isoflavone, NSC-135405, ISOFLAVONE

Patent coverage: 22,309 distinct patent families (48,036 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 48,032 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
breast neoplasm	3	MONDO:0021100	MONDO:0007254
chronic kidney disease	2	MONDO:0005300	MONDO:0024327
head and neck cancer	1	MONDO:0005627	EFO:0006859
lung adenocarcinoma	1	MONDO:0005061	EFO:0000571
squamous cell lung carcinoma	1	MONDO:0005097	EFO:0000708
lung neoplasm	1	MONDO:0021117	MONDO:0008903

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
Not specified	3
PHASE4	2
PHASE3	2
PHASE2	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00245518	PHASE4	COMPLETED	Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy
NCT03167827	PHASE4	COMPLETED	Effects of Physical Training and Isoflavone Supplementation On Pelvic Floor in Women in the Postmenopausal Period
NCT00179556	PHASE2/PHASE3	COMPLETED	Effects of Soy Isoflavones on Menopausal Hot Flashes
NCT00905723	PHASE3	UNKNOWN	The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women
NCT00925639	PHASE3	UNKNOWN	Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause
NCT00596895	PHASE2	COMPLETED	Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer
NCT01553773	PHASE2	COMPLETED	Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment
NCT01232751	Not specified	COMPLETED	Effects of Isoflavones on Gene-expression
NCT02373111	Not specified	COMPLETED	Effects of Isoflavone Combined With Astaxanthin on Skin Aging
NCT03008785	Not specified	COMPLETED	Effect of Isoflavone Supplementation Associated With Physical Exercise in the Health Parameters of Postmenopausal Women

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).